Q-omics provides the consensus-scored SLC10A5 profile across patient tissues and cancer cell-line models. SLC10A5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SLC10A5 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, SLC10A5 RNA expression shows 19,534 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, LIHC, and UVM as cancer lineages where SLC10A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC10A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC10A5 survival associations across molecular data types. SLC10A5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC10A5 RNA expression–survival associations across cancer types. High SLC10A5 expression shows unfavorable associations in COAD, UVM and KIRP, but favorable associations in BLCA, KIRC and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SLC10A5 RNA expression.
This table summarizes SLC10A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC10A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC10A5 shows lower tumor expression in LUSC, KICH, HNSC and COAD and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher SLC10A5 RNA expression in tumor versus normal tissue (log2 FC = +0.570, t-test p < 0.001).
This table shows molecular features associated with SLC10A5 in patient tissues and cancer cell lines. In patient samples, SLC10A5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC10A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
